GetHiredToday

Research assistant

Posted on: 2011-06-13

CURRICULUM VITAE

 

DANA GLOCK

 

 

 

1061 W. Madison St. #3F

Chicago, IL 60607

(312) 850-9070 home

(312) 563-2697 work

(312) 479-1415 cell

email: [email protected]

 

 

 

 

 

Summary    

Reliable and dedicated professional with 26 years in the field of                  cardiovascular research. Recognized for leadership skills, self-initiative, and exemplary work ethic. Possesses superior surgical skills. Co-developed NIH and pharmaceutical/ research protocols; engaged in manuscript preparation and presentation. Expertise in hiring, training, and supervising MD’s, PhD’s, graduate and undergraduate students. Detailed and proficient in all aspects of preclinical research.                                                                                             

 

Education

9/15/69 -         BS Degree in Basic Science/Psychology

6/15/74           University of Iowa

                        Iowa City, Iowa 52240

 

 

 

PROFESSIONAL EXPERIENCE

 

7/3/06-Present   Rush University Medical Center

            Department of Anatomy and Cell Biology

           

            Research Assistant 1

Projects included:

  • Development and Initial Application of A Rat Model for Revision Joint Replacement
  • Use of a Selective Antibody to Enhance Intramembranous Bone Formation and Implant Fixation in the Rat Ovariectomized (OVX) model
  • Study of Stem Cell Mobilization to Enhance Bone Regeneration
  • Creation, follow Up, and finalization of IACUC Research Proposals as well as IRB documentation of same
  • In vivo radiographs of animals throughout studies
  • In vitro microCT scans of bones post mortem, reconstruction of regions of interest, and 3D representation of same.
  • Preparation of bones for embedding, cutting, and slide preparation (grinding, polishing), for use in dynamic histomorphometry, scanning electron microscopy (SEM), and set up for various staining techniques.
  • Microscopic evaluation and quantification of specimen using osteomeasure, static and dynamic histomorphometry,  with fluorescence, and light microscopy.
  • Mentored Post Docs, Medical Students, Fellows, and Volunteers

 

5/19/03- 7/1/06    Rush University Medical Center

        Department of Cardiovascular-Thoracic Surgery

 

            Assistant Research Coordinator

Projects included:

  • Creation of a sheep model of ischemic heart failure using coronary artery microembolizations in order to test a new left ventricular assist device.
  • Development of mitral regurgitation in large animals.
  • Application of novel glucose biosensors to cardiovascular surgery.
  • Worked on a series of experiments using Doppler guided hemorrhoidal artery ligation in a canine model.
  • Ran training sessions for companies to explore differences between balloon catheters, drug eluting stents, and bare metal stents.
  • Tested out various catheter delivery systems.
  • Liased with medical device companies to prepare for studies using our site for training/teaching purposes, e.g., use of new gene therapy methodology.
  • Prepared budgets, submitted protocols, and filled out Internal Review Board forms.
  • Liased with medical device companies to prepare for studies using our site for training/teaching purposes.
  • Managed 10 subordinate personnel.

 

6/15/92-      Rush Presbyterian St. Luke’s Medical Center, Chicago, IL

01/06/93     Interventional Cardiology

 

                    Research Assistant 1

 

  • Research involved assessment of preclinical medical devices, 

 working closely with R&D. Looked at the effect of percutaneous

 myocardial laser revascularization on left ventricular function in a model 

 of hibernating myocardium. Studied the effect of drugs on

 myocardial injury in a swine model of ischemia and reperfusion.

 

7/1/92 -       Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL

6/15/02       Cardiology

 

                        Research Assistant I

 

  • Cardiovascular research efforts addressing septic shock. Protocols featured acute, as well as chronic preparations in swine and dogs; placement of Konigsberg pressure transducers in the apex of the left ventricle, sonomicrometer crystals, pulmonary, circumflex, and LAD flow probe placement, left atrial cannulation, and insertion of a pulmonary venous catheter, and aortic root cannula.                                          

 

 

7/15/76 -         The University of Chicago, Chicago, IL

6/92                Committee on Clinical Pharmacology

 

                        Chief Research Technologist

 

  • In charge of a cardiovascular research laboratory where investigations included the short and long term effects of experimental drugs on heart rate, blood pressure, renal, femoral, coronary and mesenteric blood flow, cardiac output, cardiac contractility, and cardioaccelerator nerve stimulation. Carried out all cardiovascular surgeries. The position also entailed supervision of technicians and graduate students, maintenance of equipment, planning and carrying out of research projects, presentation of papers at scientific meetings, and training of postdoctoral fellows.

 

 

Publications

 

  • FQ Almeda, D. Glock, J. Sanderelski, OA Ibrahim, JE Macioch, T Allen, JR Dainauskas, JE Parrillo, RJ Snell, GL Schaer: The effect of percutaneous transmyocardial laser revascularization of left ventricular function in a porcine model of hibernating myocardium. Cardiovascular Radiation Medicine 5 (2004), 132-5.

 

  • Goldfarb RD, Parker TS, Levine DM, Glock D,  Akhter I, Alkudaria  A,  McCarthy R,  Gordon B R,Sall D, Rubin AL, Trenholme G, Parrillo JE :Protein free Phospholipid emulsion treatment improved cardio-pulmonary function and survival in a porcine sepsis . American Journal Of Physiology, Integrative and Regulatory Physiology . 284(2): R550-7, 2003 Feb..

 

  • Goldfarb RD, Glock D, Akhter I, Parker T S, Levine DM, Gordon BR,  Rubin AL,  McCarthy R, Alkhudari A, Trenholme, GN, David EM,  Saal SD  Parrillo JE: Phospholipid rich emulsion improved survival in porcine model of sepsis. Am J Physiol Regul Integ & Comp Physio. 2003 Feb; 284 (2): R550-57. Epub 2002, Oct. 24.

 

  • Goldfarb RD, Guynn T, Kumar A, Glock D, McCarthy R, Li K, Trenholme G, Parrrillo JE: A porcine model of peritonitis and bacteremia closely simulates human septic shock. Shock. 1996 Dec;6(6):442-51.

 

  • Kohli JD, Horn PT, Glock D, Brewster WK, Nichols DE: Dihydrexidine: a new potent peripheral dopamine D1 receptor agonist. Eur J Pharmacol. 1993 Apr 22;235(1):31-5.

 

  • Aronson S, Goldberg LI, Glock D, Roth S, Moss J, Roizen MF: Effects of fenoldopam on renal blood flow and systemic hemodynamics during isoflurane anesthesia. J. Cardiothorac. Vasc. Anesth. 1991; 5:29-32.

 

  • Aronson S, Goldberg LI, Roth S, Glock D, Moss J, Roizen MF: Preservation of renal blood flow during hypotension induced with fenoldopam in dogs. Can. J. Anaesth. 1990; 37(3):380-84.

 

  • Lass NA, Glock D, Goldberg LI: Cardiovascular and renal hemodynamic effects of intravenous infusions of the selctive DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine. Circulation 1988; 78(5 Pt 1):1310-15.

 

  • Kohli JD, Glock D, Goldberg LI: Relative DA1-dopamine-receptor agonist and alpha-adrenoceptor antagonist activity of fenoldopam in the anesthetized dog. J. Cardiovasc. Pharmacol.1988; 11(1):123-6

 

  • Riggs RM, Nichols DE, Foreman MM, Truex LL, Glock D, Kohli JD: Specific dopamine D-1 and DA1 properties of 4-(mono- and - dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline and its tetrahydrothieno [2,3-c] pyridine analogue. J. Cardiovasc. Pharmacol. 1988; 11(1):123-6.

 

  • DeJesus OT, Van Moffaert GJ, Glock D, et al: Synthesis of a radiobrominated analog of SCH 23390, a selective dopamine D1 antagonist. J. Label Compounds Radiopharm. 1986; 23/9(919-925).

 

  • DeJesus OT, Van Moffaert GJ, Glock D, et al: Synthesis of a radiobrominated analog of SCH 23390, a selective dopamine D1 antagonist. J. Label Compounds Radiopharm. 1986; 23/9(919-925).

 

  • Barnett A, Ahn HS, Billard W, Gold EH, Kohli JD, Glock D, Goldberg LI: Relative activities of SCH 23390 and its analogs in three tests for DI/DA1 dopamine receptor antagonis00m. Eur. J. Pharmacol. 1986; 128(3):249-53.

 

  • Kohli JD, Glock D, Goldberg LI: Bulbocapnine is not a selective DA1 receptor antagonist. J. Pharm. Pharmacol. 1986; 38(5):401-2.

 

  • Goldberg LI, Kohli JD, Glock D: DA1 and DA2 dopamine receptors: Fyrther studies and clinical implications. In: Neuromodulation of Central and Peripheral Transmitter Function, “Symposia in Neuroscience”. (eds. G. Biggio, E. Costa) Liviana Press, Italy (1986).

 

  • Kohli JD, Glock D, Goldberg LI: Effects of the enantiomers of 3-PPP on DA1 and DA2 dopamine receptors in the dog. Eur J. Pharmacol. 1985; 114(3)305-10.

 

  • Nichols DE, Jacov JN, Hoffman AJ, Kohli JD, Glock D: C(2)-Methylation abolishes DA1 dopamine agonist activity of 2-amino-6, 7-dihydroxyl-1,2,3,4-tetrahydronaphthalene (6,7-ADTN): steric intolerance by the receptor. J. Med. Chem. 1984, Dec.; 27 (12): 1701-5.

 

  • Goldberg LI, Kohli JD, Glock D: Conclusive evidence for two subtypes of peripheral dopamine receptors. In: Dopaminergic Systems and their Regulation (eds. GN Woodruff JA Poar, PJ Roberts) MacMillan, London, 1986; 195-212.

 

  • Goldberg LI, Kohli JD, Glock D: Complete separation of peripheral DA1 and DA2 receptors by selective antagonists. Clin. Neuropharmacol 1984; Suppl. I, 7:802-803.

 

  • Goldberg LI, Glock D, Kohli JD, Barnett A: Separation of peripheral dopamine receptors by a selective DA1 antagonist, SCH 23390. Hypertension 1984; 6(2 Pt 2):125-30.

 

  • Kohli JD, Glock D, Goldberg LI: Selective DA2 versus DA1, antagonist activity of domperidone in the periphery. Eur. J. Pharmacol. 1983; 89(1-2):137-41.

 

  • Kohli JD, Glock D, Goldberg LI: Differential antagonisms of postsynaptic (DA1) and presynaptic (DA2) peripheral dopamine receptors by substituted benzamides. Adv. Biochem. Psychopharmacol.1982; 35: 97-108.

 

  • Grosso JA, Nichols DE, Kohli JD, Glock D: Synthesis of 2-(alkylamino)-5-6- and -6-7- dihydroxy-3,4-dihydroquinazolines and evaluation as potential dopamine agonists. J Med.Chem 1982; 22(6):703-8

 

  • Jacob JN, Nichols DE, Kohli JD, Glock D: Dopamine agonist tetrahydroisiquinolines. J Med. Chem. 1981; 24(8):1013-5.

 

  • Lertora JJ., Glock D, Stec GP, Atkinson AJ, Jr., Goldberg LI: Effects of N-acetylprocainamide and  procainamide on myocardial contractile force, heart rate, and blood pressure. Proc. Soc. Exp. Biol Med. 1979; 161(3):323-6.

 

  • Glock D, Gauron EF, Rowley VN: Effects of methylphenidate on avoidance learning in the aged rat.  J  Gen Psychol 1977; 96(2nd half):263-6.

 

 

 

ABSTRACTS

 

 

  • R Higgins, D Glock, K Abe, A Perez-Tamayo, E Savage, J Dainauskas, M Piel, P. McMullin, B Galbut, C Kavinsky: Chronic congestive heart failure utilizing microembolization of the coronary circulation in sheep- lessons learned and future considerations. Rush Forum, Rush University Medical Center, 2005.

 

  • FQ Almeda, D. Glock, J. Sanderelski, OA Ibrahim, JE Macioch, T Allen, JR Dainauskas, JE Parrillo, RJ Snell, GL Schaer: The effect of percutaneous transmyocardial laser revascularization of left ventricular function in a porcine model of hibernating myocardium. Cardiovascular Radiation Medicine 5 (2004), 132-5.

 

  • FQ Almeda, D. Glock, J. Sanderelski, OA Ibrahim, JE Macioch, T Allen, JR Dainauskas, JE Parrillo, RJ Snell, GL Schaer: The effect of percutaneous transmyocardial laser revascularization of left ventricular function in a porcine model of hibernating myocardium: A pilot study. Catheterization and cardiovascular interventions, May 2003, 59(1); 104: A-40..

 

  • Yaacoub A, Glock D, Nichols DE, Kohli JD: Renal effects of intravenous dihydrexidine, a new selective DA1 dopamine receptor agonist in the dog. Clin. Res. 1991; 39:264:A.

 

  • Gretler DD, Glock D, Murphy MB: Acute blood pressure reduction with fenoldopam and nitroprusside: Effects on coronary blood flow. Clin. Res. 1991; 39:263A.

 

  • Walker R, Wiencek JG, Zaroff J, Heidenreich P, Bilotta F, Glock D, Aronson S, Feinstein SB, Harper PV: Pitfalls in quantitation of contrast echo: Threshold effects. J. Am. Soc. Echocardiogr. 1991; in press.

 

  • Kohli JD, Glock D, Brewster WK, Noerzer T, Nichols DE: A new potent and selective DA1 (vascular) dopamine receptor agonist. Eur. J. Pharmcol. 1990; 183/4 (pp.1287).

 

 

  • Aronson S, Wiencek JG, Zaroff JG, Heidenreich PA, Glock D, Feinstein SB, Roizen MF: Assessment of renal blood flow in the dog with contrast ultrasound. Anesth. Analg. 1990; 70:S10.

 

  • Kohli JD, Goldberg LI, Glock D, Clark BJ, Seiler MP: DY 208-243 (-)-4, 6, 6a, 7, 8, 12b-hexahydro-7-methylindolo [4, 3-ab]-phenanthridine, (CY), a benzergoline with DA1 dopamine receptor agonist activity. FASEB 1989; 3:A533, #2107.

 

  • Heidenreich PA, Aronson S, Feinstein SB, Wiencek JG, Glock D, Zaroff G, Park T, Goldberg LI, Roizen MF, Harper PV: In vivo calculation of blood flow with contrast ultrasonography. Circulation 1989; 80:11-566.

 

  • Satoh Y, Kohli JD, Glock D, Goldberg LI: DA1 dopamine receptor agonist potency of fenoldopam in the canine intra-arterial renal assay. FASEB 1988; 2:A384, #511.

 

 

  • Kohli JD, Glock D, Goldberg LI, Cannon JG: DA1 mediated renal vasodilation produced by TL-333 and TL-99 in the dog is unmasked by rauwolscine. FASEB 1988; 2:A384, #511.

 

  • Aronson S, Ross S, Glock D, Goldberg LI, Moss J, Roizen MF: Effects of fenoldopam on renal blood flow and systematic hemodynamics during isoflurane anesthesia in dogs. Anesthesiology 1988; 69:A34.

 

  • Aronson S, Roth S, Glock D, Goldberg LI: Preservation of renal blood during controlled hypotension with fenoldopam. Clin. Res. 1987; 35:881A.

 

  • Kohli JD, Weinstock J, Glock D, Goldberg LI: Dopamine receptor activities of benzothiazol -2 one analogs of dopamine. Xth International Congress Pharmcol 1987; Abstract P1311.

 

  • Lass NA, Bakris GL, Glock D, Goldberg LI: Alpha-adrenoceptor contribution to renal vascular effects of low-dose dopamine. Clin. Res. 1987; 35:644A.

 

  • DeJesus OT, Van Moffaert GJ, Glock D, et al: Synthesis of a radiobrominated analog of SCH 23390, a selective dopamine D1 antagonist. J.Label Compounds Radiopharm. 1986; 23/9(919-925).

 

  • Metra M, Kohli JD, Glock D, Goldberg LI: Subtype of the dopamine (DA) receptor in the stellate ganglion of the dog. Fed. Proc. 1986; 45:195 #241.

 

  • Goldberg LI, Kohli JD, Glock D: DA1 agonist versus alpha-adrenoceptor antagonist activity of fenoldopam in the dog. Fed. Proc. 1986; 45:195 #241.

 

  • Murphy MB, Glock D, Lubbers NL, Goldberg LI: Effects of atrial natriuretic factor are independent of dopamine (DA1) receptor activation. Clin. Res. 1986; 34:712A.

 

  • Lass N, Goldberg LI, Lubbers N, Glock D: Cardiac and renal vascular effects of the selective DA1 agonist, fenoldopam, alone and combined with dobutamine. Clin. Res. 1986; 34:638A.

 

  • Kohli JD, Glock D, Goldberg LI, et al: Analogs of SCH 23390 in physiological biochemical and ligand binding models of the dopamine (DA) receptor. Fed Proc. 1985; 44/6 (No. 8287).

 

  • Glock D, Kohli JD, Goldberg LI: DA2 antagonist activity of Lilly 141865 (trans- (+ or -)-4, 4a, 5, 6, 7, 8, 8a, 9-octahydro-5 propyl -2h-pyrazolo (3, 4- g) quinolinedihydrochloride biochemical and ligand binding models of the dopamine (DA) receptor. Fed. Proc. 1984; 43/3 (No. 1593).

 

  • Kohli JD, Glock, Goldberg LI: Conclusive evidence for two subtypes of peripheral dopamine (DA) receptors. IUPHAR, 9th International Congress of Pharmacology, London, 1984; Abstract #1417.

 

 

  • Goldberg LI, Glock D, Kohli JD, Gerger J: Separation of peripheral DA receptors by a selective DA1 antagonist. Clin. Res. 1983; 31:716A.

 

  • Goldberg LI, Kohli JD, Glock D: Peripheral dopamine receptor activity of the enantiomers of 3-(hydroxyphenyl)-N-n-propylpiperidine (3-PPP). Fed. Proc. 1983; 42(3):382 #523.

 

  • Glock D, Kohli JD, Goldberg LI: Domperidone: A potent and highly selective DA2, peripheral dopamine receptor, antagonist. Fed. Proc. 1982; 41/5(No. 8077).

 

  • Glock D, Goldberg LI, Kohli JD: Differential peripheral dopamine (DA) receptor antagonism by intravenous injections (R)-and (S)-sulpride. Fed. Proc.1981; 40/31(318).

 

  • Goldberg LI, Glock D, Kohli JD, McDermed J: Dopamine vascular activity of 2-dipropylamino-5,6-dihydroytetralin (diropyl-A-5, 5-DTN). Fed Proc. 1981; 40/31(317).

 

  • Glock D, Goldberg LI, Kohli JD: AHR-6092 (5-aminosulfonyl)-N-(1-cyclohexyl-3-pyrolidinyl)-2 methoxybenzamide), a selective antagonist of the presynaptic dopamine receptor.
  • Lertora JJL, Glock D, Stec GP, et al: Effects on N-acetylprocainamide and procainamide on myocardial contractile force. Fed. Proc. 1979; 38/31(No. 2473).

 

  • Glock D, Kohli JD, Goldberg LI: Substituted benzamides as antagonists of dopamine-induced renal vasodilation. Fed. Proc. 1979; 38/31(No. 2759).

 

  • Kohli JD, Volkman PH, Glock D, Goldberg LI: Metoclopramide and sulpride: Antagonists of the vascular dopamine receptor. Fed. Proc. 1978; 37/3(No. 3035).

 

 

 

 

 

PRESENTATIONS

 

 

  • Further Evidence Corroborating the Similarity of the DA1 Receptor.
    • FASEB Anaheim, California (1985)
    • Conclusive Evidence for Two Subtypes of Peripheral Dopamine (DA) Receptors.
    • 9th International Congress of Pharmacology
    • (IUPHAR) London, United Kingdom (1984)

 

  • DA2 Antagonist Activity of Lilly 141865 (trans-(+)-4, 4a, 5, 6, 7, 8, 8a, 9-octahyfro-5-propyl-2H-pyrazolo [3, 4-g] quinoline dihydrochloride).
    • FASEB St. Louis, Missouri (1984)
    • Peripheral Dopamine (DA) Receptor Activity of the Enantiomers of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP).
    • FASEB Chicago, Illinois

 

  • Domperidone: A Potent and Highly Selective DA2 Peripheral Dopamine receptor Antagonist.
    • FASEB New Orleans, Louisiana (1982)

 

  • Differential Peripheral Dopamine receptor Antagonism by Intravenous Injections of (R) - and (S) - Sulpiride.
    • FASEB Atlanta, Georgia (1981)

 

  • AHR-6092 (5-aminosulfonyl)-N-(1cyclohesyl-3 pyrrolidiny)-2 methoxybenzamide), a Selective Antagonists of the Presynaptic Dopamine Receptor.
    • FASEB Anaheim, California (1980)

 

  • Submitted Benzamides as Antagonists of DA-Induced Renal Vasodilation.
    • FASEB Dallas, Texas (1979)

 

  • Metoclopramide and Sulpiride: Antagonists of the Vascular DA Receptor.

 

  • Federation of American Societies for Experimental Biology FASEB
    • FASEB Atlantic City, New Jersey (1978)